Skip to main content
Samer Srour, MD, Hematology, Houston, TX, Oklahoma City VA Medical Center

SamerSrourMD

Hematology Houston, TX

Myeloproliferative Disorder Hematology-Oncology

Physician

Are you Dr. Srour?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 33 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Samer Srour, MD is a hematologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital
    Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 2006 - 2009
  • Beirut Arab University Faculty of Medicine
    Beirut Arab University Faculty of MedicineClass of 2003

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2015 - 2025
  • OK State Medical License
    OK State Medical License 2008 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

Press Mentions

  • Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
    Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
  • Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
    Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual MeetingMarch 15th, 2023
  • Updated Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy
    Updated Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell TherapyDecember 20th, 2022
  • Join now to see all

Hospital Affiliations